🔗 Share this article

Given that the United States continues making historic changes to its immunization recommendations, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on coronavirus shots during the global health crisis and has zeroed in on possible fatalities after Covid immunization in her short time at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Schedule

Public health authorities were set to announce radical changes to the childhood vaccine schedule recently, aligning the US with Denmark’s national calendar, it is understood – a significant shift that would place the US out of alignment with a large portion of the world with no evidence for improved outcomes. This reveal has been delayed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to head the center this year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the drug and biologics branches as Høeg and Prasad strengthen their influence at the agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric immunization guidelines in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a citizenry about the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – usually the responsibility of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Questions Over Background

The appointee has little discernible track record in pharmaceutical research, approval processes or leadership, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Previous directors of CBER would “understand laws and regulations and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who led the center have had.”

The drug center has an vast range of responsibilities at the agency, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and every single one need to be looked after,” Dr. Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a major leadership aspect to the position, which supervises over 5,000 staff members. “It is a enormous leadership role, if you do it right,” she added.

Response and Contentious Initiatives

In response to concerns about Høeg’s credentials and whether this selection signifies more teamwork among regulatory chiefs on vaccines, a spokesperson said that the “questions rely on inaccurate assumptions”.

“This background is consistent with the duties of her position,” the spokesperson said, noting the time Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s controversial priority voucher program, a controversial expedited medication authorization process that allegedly worried her former heads. “By what process are these drugs being selected for this fast-track system? Who makes the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the agency right now.”

In general, he stated, “the FDA appears to be shifting towards laxer regulations of pharmaceuticals, except for vaccines.”

Established History on Vaccines

Concerning vaccines, Høeg has a more documented, if troubling, history, Howard observe. She authored a study using non-validated volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the new administration included revising regulations for new vaccines and discontinuing “unnecessary” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has according to sources floated the idea of preventing adolescent males from getting COVID-19 vaccinations.

“She is an complete dogmatist who starts off with her preconceived notions and tailors the evidence to retrofit the evidence in a highly disingenuous, dishonest manner,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg joined fellow dissenters, {like|